In IBD animal models, these DNase I nanozymes not only alleviated key pathological features but also significantly reduced neutrophil infiltration and NETosis compared with free DNase I or mesalamine [212]. This evidence concerns the gene DNASE1L3 and irritable bowel syndrome.